Dr Reddy’s Is Latest Rumored Buyer For Biogen’s Biosimilars
Reports Suggest Firm Has Thrown Its Hat Into The Ring, Following Samsung Bioepis And Intas
Executive Summary
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
You may also be interested in...
Samsung Bioepis Responds To Rumor Of Biogen Biosimilars Buyout
Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.
Biogen Sees Interest In Potential Biosimilars Deal
As Biogen provided an update on a potential sale of its biosimilars business – with the firm “engaged with multiple interested parties” – it also revealed Q2 sales and offered insights into off-patent competition to its Tysabri and Tecfidera brands.
Dr Reddy’s Moves Ahead With Global Rituximab Filings
Dr Reddy’s has celebrated a “milestone” for its biosimilars business after disclosing that multiple regulators in Europe and the US have accepted its rituximab filings for review.